Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 29, 2014

View Archived Issues

Korean group prepares new monoclonal antibodies

Cedars-Sinai begins phase I trial of brain cancer vaccine

Venaxis completes enrollment in pivotal U.S. trial of APPY1 Test for appendicitis

GERD linked to FOXF1 and MHC locus gene polymorphisms

Researchers at Esteve design novel sigma1 receptor ligands

Tekmira commences phase I trial of TKM-100802

New casein kinase 2 inhibitors disclosed by Bristol-Myers Squibb

Genentech and Roche disclose new ROR-gamma modulators

PARSiFAL trial to investigate BAY-1067197 in heart failure

Mallinckrodt begins patient recruitment in phase I trial of MP-3549.1 in advanced solid tumors

Patient recruitment begins in phase I trial of Ribological's personalized anticancer vaccine

Transgene prepares novel tuberculosis vaccines

DioGenix discloses new data supporting efficacy of multiple sclerosis assay

Maruho to take over marketing rights for Protopic ointment in Japan

Data presented from AIMSPRO study in diffuse systemic sclerosis

OncoCyte commences clinical development of bladder cancer diagnostics in U.S. and China

Alcobra reports promising results from new study of MG-01CI in animal model of fragile X syndrome

Phase I study of A*STAR and Cytos' H1N1 influenza vaccine meets primary immunogenicity endpoint

FDA committee recommends approval of Ragwitek BLA

Amgen's LAPLACE-2 phase III trial of evolocumab in combination with statins meets primary endpoints

Oncolys BioPharma commences phase I/II trial of Telomelysin in Korea and Taiwan

Sosei offers development update on glycopyrronium bromide programs

VCN Biosciences to advance VCN-01 oncolytic adenovirus to clinic

PARP-1 inhibitors developed at Lupin

Astellas reports melatonin agonists for urinary incontinence

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...